Overview

Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome

Status:
Completed
Trial end date:
1992-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of two surfactants, Exosurf Neonatal (Burroughs Wellcome Co.) and Survanta (Ross Laboratories), for the treatment of neonatal respiratory distress syndrome.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
NICHD Neonatal Research Network
Treatments:
Beractant
Pulmonary Surfactants